Sanghoon Shin1, Hyung-Bok Park2, Hyuk-Jae Chang3, Reza Arsanjani4, James K Min5, Yong-Jin Kim6, Byoung Kwon Lee7, Jung-Hyun Choi8, Geu-Ru Hong9, Namsik Chung9. 1. Division of Cardiology, Department of Internal Medicine, NHIS Ilsan Hospital, Goyang-si, Gyeonggi-do, South Korea; Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Yonsei University Health System, Seoul, South Korea. 2. Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Yonsei University Health System, Seoul, South Korea; Division of Cardiology, Department of Internal Medicine, Myungji Hospital, Goyang-si, Gyeonggi-do, South Korea. 3. Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Yonsei University Health System, Seoul, South Korea. Electronic address: hjchang@yuhs.ac. 4. Mayo Clinic, Division of Cardiology, Department of Internal Medicine, Scottsdale, Arizona. 5. Weill Cornell Medical College and the New York-Presbyterian Hospital, New York, New York. 6. Division of Cardiology, Seoul National University Hospital, Seoul, South Korea. 7. Division of Cardiology, Gangnam Severance Hospital, Seoul, South Korea. 8. Division of Cardiology, Busan Medical Center, Busan, South Korea. 9. Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Yonsei University Health System, Seoul, South Korea.
Abstract
OBJECTIVES: The aim of this study was to explore the relationship between temporal changes in coronary plaque volume and the intensity of lipid-lowering treatments, utilizing coronary computed tomography angiography (CTA). BACKGROUND: Coronary CTA has acceptable accuracy in terms of quantitative measurement of plaque volume. Although, coronary CTA is perhaps capable of identifying the differences in plaque volume progression according to the intensity of lipid lowering treatment, to date, few studies have examined this notion. METHODS: In this multicenter, observational study, the authors reviewed 467 patients who underwent serial coronary CTA with a scan period of more than 2 years (median 3.2 years [2.4 to 4.8]) apart, and whose laboratory data were available within 1 month of both the baseline and follow-up coronary CTA. Among them, 147 patients (comprising 336 vessels) with visible plaque were enrolled in this study. The authors performed quantitative assessment of coronary plaque in both. Patients who achieved a low-density lipoprotein cholesterol (LDL-C) with a cut off value below 70 mg/dl at follow-up were compared with those who did not. RESULTS: Patients with LDL-C below 70 mg/dl displayed a significant attenuation in plaque progression as compared with those with follow-up LDL-C levels ≥70 mg/dl (12.7 ± 38.2 mm3 vs. 44.2 ± 73.6 mm3, respectively; p = 0.014). In multivariate analysis, factors influencing plaque progression per year was follow-up LDL-C levels ≥70 mg/dl (beta 0.193; p = 0.021). CONCLUSIONS: Strict LDL-C control appeared to significantly attenuate plaque volume progression based on noninvasive quantitative assessment by coronary CTA.
OBJECTIVES: The aim of this study was to explore the relationship between temporal changes in coronary plaque volume and the intensity of lipid-lowering treatments, utilizing coronary computed tomography angiography (CTA). BACKGROUND: Coronary CTA has acceptable accuracy in terms of quantitative measurement of plaque volume. Although, coronary CTA is perhaps capable of identifying the differences in plaque volume progression according to the intensity of lipid lowering treatment, to date, few studies have examined this notion. METHODS: In this multicenter, observational study, the authors reviewed 467 patients who underwent serial coronary CTA with a scan period of more than 2 years (median 3.2 years [2.4 to 4.8]) apart, and whose laboratory data were available within 1 month of both the baseline and follow-up coronary CTA. Among them, 147 patients (comprising 336 vessels) with visible plaque were enrolled in this study. The authors performed quantitative assessment of coronary plaque in both. Patients who achieved a low-density lipoprotein cholesterol (LDL-C) with a cut off value below 70 mg/dl at follow-up were compared with those who did not. RESULTS:Patients with LDL-C below 70 mg/dl displayed a significant attenuation in plaque progression as compared with those with follow-up LDL-C levels ≥70 mg/dl (12.7 ± 38.2 mm3 vs. 44.2 ± 73.6 mm3, respectively; p = 0.014). In multivariate analysis, factors influencing plaque progression per year was follow-up LDL-C levels ≥70 mg/dl (beta 0.193; p = 0.021). CONCLUSIONS: Strict LDL-C control appeared to significantly attenuate plaque volume progression based on noninvasive quantitative assessment by coronary CTA.
Authors: Ranganath Muniyappa; Radwa A Noureldin; Khaled Z Abd-Elmoniem; Riham H El Khouli; Jatin Raj Matta; Ahmed Hamimi; Siri Ranganath; Colleen Hadigan; Lynnette K Nieman; Ahmed M Gharib Journal: Cardiorenal Med Date: 2018-03-26 Impact factor: 2.041
Authors: Donghee Han; Daniel S Berman; Robert J H Miller; Daniele Andreini; Matthew J Budoff; Filippo Cademartiri; Kavitha Chinnaiyan; Jung Hyun Choi; Edoardo Conte; Hugo Marques; Pedro de Araújo Gonçalves; Ilan Gottlieb; Martin Hadamitzky; Jonathon Leipsic; Erica Maffei; Gianluca Pontone; Sangshoon Shin; Yong-Jin Kim; Byoung Kwon Lee; Eun Ju Chun; Ji Min Sung; Sang-Eun Lee; Renu Virmani; Habib Samady; Peter Stone; Jagat Narula; Jeroen J Bax; Leslee J Shaw; Fay Y Lin; James K Min; Hyuk-Jae Chang Journal: JAMA Netw Open Date: 2020-07-01